ISIS PHARMACEUTICALS INC

CARLSBAD, CA · CIK 0000874015 · Biotech · Public

Small molecule and antisense oligonucleotide therapeutics for rare and serious diseases

ionis.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$201M
1 Form D · Aug 2012
169 months since last filing
Contracts
—
No federal contracts on record
Patents
40
29 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$201,250,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2376BIOINVENU CORPORATION——
2377DNP THERAPEUTICS INC—$470K
2378XFIBRA, INC.——
2379ISIS PHARMACEUTICALS INC—$201M
2380MANUS BIO INC—$109M
2381Jaguar Health, Inc.—$146M
2382MediWound Ltd.—$31M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • C BENNETTExecutive Officer
  • SPENCER BERTHELSENDirector
  • STANLEY CROOKEDirector · Executive Officer
  • RICHARD GEARYExecutive Officer
  • JOSEPH KLEIN IIIDirector
  • BRETT MONIAExecutive Officer
  • FREDERICK MUTODirector
  • B PARSHALLDirector · Executive Officer
  • JOHN REEDDirector
  • JOSEPH WENDERDirector

Patents

USPTO · 29 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.